17,261 trials
Osteomyelitis
Primary: Percentage of Participants With Clinical Response at Day 42 in the Clinically Evaluable (CE) Population — 97.0; 87.5; 0.0; 12.5 percentage of participants
Basal Cell Carcinomas
Primary: Number of Treatment-emergent Adverse Events (Including Both Serious and Non-Serious) Causally Related to Study Drug — 0; 0; 0; 2 number of events
Psoriasis
Primary: Psoriasis Area Severity Index — 5.5; 5.0 score on a scale
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome · Adult Acute Lymphoblastic Leukemia in Remission · Adult Acute Megakaryoblastic Leukemia (M7)
Primary: Overall Survival — 8 Participants
Hepatitis B
Primary: Concentrations of Cytokines and Chemokines - Step 1 — 6000; 6250; 14; 14 pg/mL
Anxiety · Abdominal Pain
Primary: Change in Child Abdominal Pain Rating — 0.36 units on a scale
Thrombocytopenia · Alloimmune Platelet Refractoriness
Primary: Number of Subjects With Sustained Platelet Transfusion Responsiveness — 4 Participants
HIV Infections
Primary: Serious Adverse Events — 0; 17; 0; 6 Participants
Ovarian Cancer
Primary: Adverse Events Related to Study Treatment — 5 Participants
Multiple Myeloma
Primary: Adverse Events Related to Study Treatment — 24 participants
Lung Cancer
Primary: Maximally Tolerated Dose (MTD) (Phase I) — 150; 20 mg
Oral Chronic Graft vs Host Disease
Primary: Percentage of Participants With a Response as Assessed by the 273-point Oral Mucositis Rating Scale (OMRS) Who Received Topical Clobetasol 0.05% Oral Rinse for Oral…
Non-Small Cell Lung Cancer · Breast Cancer · Pancreatic Cancer
Primary: Phase 1b: Number of Participants With Adverse Events as a Measure of Safety and Tolerability of Ibrutinib and Durvalumab (MEDI4736) and to Find the Recommended Phase II…
Breast Cancer
Primary: Progression-Free Survival (PFS) — 3.7; 3.6 months — p=0.79
Recurrent Renal Cell Carcinoma · Stage III Renal Cell Cancer · Stage IV Renal Cell Cancer
Primary: Response Rate (Confirmed Complete Response or Partial Response), Determined According to Response Evaluation Criteria in Solid Tumors — 0; 0; 0; 0 Participants